Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
RESEARCH TOOLSreports
Holding NAUT?
Track your performance easily
NAUT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.61 - $3.12
Previous CloseN/A
Volume36.21K
Average Volume (3M)157.24K
Market Cap
$238.57M
Enterprise Value$248.50M
Total Cash (Recent Filing)$345.73M
Total Debt (Recent Filing)$29.06M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Feb 20, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding125,563,965
10 Day Avg. Volume128,289
30 Day Avg. Volume157,239
Standard Deviation0.15
R-Squared0.15
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.93
Forecast
1Y Price Target
$5.00Price Target Upside159.07% Upside
Rating ConsensusHold
Number of Analyst Covering3
Nautilus Biotechnolgy News
PremiumCompany Announcements
Nautilus Biotechnology Reports Q3 2024 Financial Results
PremiumPre-Earnings
Is NAUT a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Commercialization ProspectsManagement expressed a high degree of confidence in being on a path to a full commercial launch of their PriSM technology for broadscale discovery.
Financial StrategyPrudent cost management enables cash runway to extend into 2027.
Technological DevelopmentProgress towards developing a differentiated proteomics offering and continued cash management remains encouraging.
Bears Say
Commercial LaunchStock upside likely limited pending commercial launch.
Internal MilestonesBehind on internal milestones towards being able to quantify a significant number of proteins from a complex sample.
Product DevelopmentTimelines slipped again given ongoing efforts to develop commercial-ready probes for its single molecule proteome tech.
---
Ownership Overview
42.95% Insiders
3.83% Mutual Funds
0.02% Other Institutional Investors
49.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NAUT FAQ
What was Nautilus Biotechnolgy’s price range in the past 12 months?
Nautilus Biotechnolgy lowest stock price was $1.61 and its highest was $3.12 in the past 12 months.
What is Nautilus Biotechnolgy’s market cap?
Nautilus Biotechnolgy’s market cap is $238.57M.
When is Nautilus Biotechnolgy’s upcoming earnings report date?
Nautilus Biotechnolgy’s upcoming earnings report date is Feb 20, 2025 which is in 30 days.
How were Nautilus Biotechnolgy’s earnings last quarter?
Nautilus Biotechnolgy released its earnings results on Oct 29, 2024. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.165 by $0.035.
Is Nautilus Biotechnolgy overvalued?
According to Wall Street analysts Nautilus Biotechnolgy’s price is currently Undervalued.
Does Nautilus Biotechnolgy pay dividends?
Nautilus Biotechnolgy does not currently pay dividends.
What is Nautilus Biotechnolgy’s EPS estimate?
Nautilus Biotechnolgy’s EPS estimate is -0.15.
How many shares outstanding does Nautilus Biotechnolgy have?
Nautilus Biotechnolgy has 125,563,965 shares outstanding.
What happened to Nautilus Biotechnolgy’s price movement after its last earnings report?
Nautilus Biotechnolgy reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.165. Following the earnings report the stock price went down -1.423%.
Which hedge fund is a major shareholder of Nautilus Biotechnolgy?
Among the largest hedge funds holding Nautilus Biotechnolgy’s share is Perceptive Advisors LLC. It holds Nautilus Biotechnolgy’s shares valued at 36M.
---
Nautilus Biotechnolgy Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.00 (159.07% Upside)
$5.00 (159.07% Upside)
Hedge Fund Trend
Increased
By 20.0K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.23%
12-Months-Change
Fundamentals
Return on Equity
-28.04%
Trailing 12-Months
Asset Growth
-18.42%
Trailing 12-Months
Company Description
Nautilus Biotechnolgy
ARYA Sciences Acquisition Corp III is a blank check company.
---
NAUT Company Deck
---
NAUT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in proteoform data and cash management, yet challenges remain in achieving broadscale discovery milestones and probe candidate performance. Plans for commercial launch in late 2025 are still on track.Read More>---
NAUT Stock 12 Month Forecast
Average Price Target
$5.00
▲(159.07% Upside)
Technical Analysis
Singular Genomics Systems
―
Quantum-Si
―
Seer
―
Twist Bioscience
―
10x Genomics
―
Ginkgo Bioworks Holdings
―
Best Analysts Covering NAUT
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-23.15%
assigned a buy rating 3 months ago
Copying Daniel Brennan's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -23.15% per trade.
---